^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Tubulin polymerization promoter

    Related drugs:
    1d
    A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer (clinicaltrials.gov)
    P1, N=28, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    MSK-IMPACT
    |
    carboplatin • paclitaxel
    2d
    BARCODE2: The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment (clinicaltrials.gov)
    P2, N=305, Active, not recruiting, Institute of Cancer Research, United Kingdom | Trial completion date: Sep 2025 --> Dec 2028 | Trial primary completion date: Sep 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    carboplatin
    2d
    Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma (clinicaltrials.gov)
    P1/2, N=31, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2026 --> May 2026 | Trial primary completion date: Jan 2026 --> May 2026
    Trial completion date • Trial primary completion date
    |
    gemcitabine • docetaxel • hydroxychloroquine
    2d
    Primary Gastric Adenocarcinoma with Thyroid Transcription Factor-1 Positivity Mimicking Gastric Metastasis from Lung Cancer: A Case Report. (PubMed, Surg Case Rep)
    This case highlights the diagnostic challenge posed by TTF-1-positive gastric tumors, which may be mistaken for metastatic lesions from lung cancer. As TTF-1 expression is not entirely specific to tissues of lung or thyroid origin, diagnosis should be based on a comprehensive evaluation of morphological and immunohistochemical findings, together with clinical information, including treatment response and disease course.
    Journal • PD(L)-1 Biomarker
    |
    TTF1 (Transcription Termination Factor 1) • NKX2-1 (NK2 Homeobox 1) • CDX2 (Caudal Type Homeobox 2) • NAPSA (Napsin A Aspartic Peptidase)
    |
    Keytruda (pembrolizumab) • carboplatin • pemetrexed
    4d
    CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy. (PubMed, Cancer Res Commun)
    Post-carboplatin analysis revealed increased CLDN6 expression, EMT-related gene changes, and enhanced T-cell infiltration, which were associated with the synergistic effect of SAIL66. Our study provides insights into the biology and plasticity of CLDN6-positive cells in EOC heterogeneity and highlights the clinical significance of CLDN6-targeting therapies for ovarian cancer treatment.
    Journal • IO biomarker
    |
    CLDN6 (Claudin 6)
    |
    carboplatin • SAIL66
    4d
    Impact of Immunohistochemical PSA and Ki-67 Expression on Prognosis in Metastatic Castration-Sensitive Prostate Cancer. (PubMed, Int J Urol)
    Immunohistochemical PSA and Ki-67 expression provide practical prognostic information for patients with metastatic castration-sensitive prostate cancer. Combined assessment with EOD ≥ 3 identifies a high-risk subgroup with unfavorable clinical outcomes.
    Clinical • Retrospective data • Journal
    |
    KLK3 (Kallikrein-related peptidase 3)
    |
    docetaxel • Nubeqa (darolutamide)
    5d
    PBX1-mediated transcription of AP1M2 promotes triple-negative breast cancer malignant progression and docetaxel resistance. (PubMed, Gene)
    PBX1-mediated AP1M2 facilitates cell proliferation, migration, invasion, and docetaxel resistance to accelerate TNBC malignant behavior, providing a novel target for TNBC treatment.
    Journal
    |
    PBX1 (PBX Homeobox 1)
    |
    docetaxel
    6d
    Efficacy and safety of All-site Radiation therapy and Standard Of Care Therapy with or without Docetaxel for GG5 metastatic Prostate Cancer: A Ambispective Cohort Study (ChiCTR2500112793)
    P=N/A, N=520, Not yet recruiting, Peking University First Hospital; Peking University First Hospital
    New trial
    |
    docetaxel
    6d
    A study on the treatment of advanced gastric/gastroesophageal junction adenocarcinoma with docetaxel for injection (albumin-bound type) combined with oxaliplatin and 5-FU/LV (ADOF) (ChiCTR2500112147)
    P=N/A, N=12, Not yet recruiting, Fujian Cancer Hospital; CSPC Zhongqi Pharmaceutical Technology Co., Ltd.
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
    |
    PD-L1 expression • MSI-H/dMMR • HER-2 overexpression
    |
    5-fluorouracil • oxaliplatin • albumin-bound docetaxel (CPO100)
    6d
    Efficacy and Safety of Epalolitovorellizumab in Combination with Docetaxel in Advanced Non-Small-Cell Lung Cancer Progressing After First-Line Immunotherapy (ChiCTR2500112069)
    P=N/A, N=33, Not yet recruiting, Yantai Yuhuangding Hospital; Yantai Yuhuangding Hospital
    New trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    docetaxel
    6d
    A single-arm exploratory clinical trial of Utidelone injection for advanced pancreatic cancer refractory to standard therapy (ChiCTR2500112307)
    P=N/A, N=48, Recruiting, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine; Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
    New trial
    |
    utidelone IV (UTD1)
    6d
    Study on the efficacy of Utidelone combined with Anotinib in the treatment of advanced Non-Small Cell Lung Cancer (ChiCTR2500115269)
    P2, N=61, Not yet recruiting, Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen Un
    New P2 trial
    |
    ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK positive • ALK fusion
    |
    Focus V (anlotinib) • utidelone IV (UTD1)